内镜下黏膜切除术和内镜黏膜下剥离术治疗直肠类癌的对照研究

目的 评估内镜下黏膜切除术(EMR)和内镜黏膜下剥离术(ESD)治疗直肠类癌的有效性及安全性.方法 回顾性总结24例26处EMR治疗(EMR组)和19例20处ESD治疗(ESD组)的直肠类癌患者的临床资料,对比分析两组在病灶大小、手术时间、病灶整块切除率、组织病理学治愈性切除率、并发症及随访结果方面的差异.结果 ESD组术前超声内镜测量的直径大小为(7.4 ±5.3)mm,明显大于EMR组的(5.6 ±2.1)mm(P ＜0.05);ESD组手术时间为(32.6±10.5)min,明显长于EMR组的(8.9±6.3)min(P ＜0.05);EMR组和ESD组病灶均一次性完整切除,整块切除率均为100.0％;EMR组的组织病理学治愈性切除率为100.0％(26/26),略高于ESD组的95.0％ (19/20) (P＞0.05);EMR术后出血、穿孔并发症发生率为15.3％ (4/26),明显高于ESD组的5.0％ (1/20) (P＜0.05);两组在术后复查随访,均未发现局部复发.结论 对于直径小于7 mm的病灶应用EMR方法可以有效完整地切除病灶,并缩短手术时间;而对于直径大于7 mm和经过多次活检或局部切除后内镜下注射抬举征阴性的病灶,采取ESD的手术方式,方能得到比较满意的治疗效果.     

内镜下黏膜剥离术治疗消化道黏膜增生性病变88例分析

目的探讨内镜下黏膜剥离术(ESD)治疗消化道黏膜增生性病变的临床疗效。方法将宜兴市人民医院收治的消化道黏膜增生性病变患者88例,随机分成内镜下黏膜切除术(EMR)组(44例)和ESD组(44例)。术后随访12个月,观察两组的临床疗效及穿孔、出血等并发症及复发情况。结果与EMR组比较,ESD组的手术时间明显增加,但一次性切除率明显升高(P0.05);术后6个月,ESD组切面愈合率显著高于EMR组(P0.05),ESD组术后12个月的复发率显著低于EMR组(P0.05)。结论与EMR相比,ESD治疗消化道黏膜增生性病变的一次性切除率和术后切面愈合率均较高,且术后12个月的复发率较低。     

内镜下经多隧道黏膜下剥离术和内镜黏膜下剥离术治疗消化道早癌及癌前病变的疗效及安全性

目的比较内镜下经多隧道黏膜下剥离术(ESMTD)和内镜黏膜下剥离术(ESD)治疗消化道早癌及癌前病变的疗效及安全性,探讨ESMTD和ESD在消化道早癌及癌前病变的治疗价值。方法选取消化道早癌及癌前病变患者140例。依据手术方式不同,分为ESMTD组(38例)和ESD组(102例)。比较两组术后病灶整块切除率、根治性切除率、操作时间、住院时间、并发症、疼痛程度及随访3、6、12个月的复发率、生活质量核心30问卷调查(QLQ-C30)评分。结果ESMTD组患者术后在整块切除率、根治性切除率明显高于ESD组,在操作时间、住院时间明、术后疼痛程度显著低于ESD组,差异有统计学意义(P<0.05)。ESMTD组术后并发症发生率显著低于ESD组,差异有统计学意义(P<0.05)。ESMTD组和ESD组在术后3个月均无复发病例,ESMTD组在术后6、12个月复发率低于ESD组,差异没有统计学意义(P>0.05);ESMTD组在术后3、6、12个月QLQ-C30量表评分均显著高于ESD组,差异有统计学意义(P<0.05)。结论ESMTD和ESD治疗消化道早癌及癌前病变疗效显著,且ESMTD在术后病灶整块切除率、根治性切除率、操作时间、住院时间、并发症、疼痛程度及复发率、QLQ-C30评分方面明显优于ESD,安全性较好。     

内镜黏膜下剥离术与内镜黏膜切除术治疗早期胃癌患者的疗效比较

[目的]探究内镜黏膜下剥离术(ESD)与内镜黏膜切除术(EMR)治疗早期胃癌患者的疗效。[方法]选取2014-02—2016-12我院收治的186例早期胃癌患者,根据治疗方法的不同分为ESD组和EMR组,ESD组采用ESD进行治疗,EMR组采用EMR进行治疗,观察比较2组患者手术时间、住院时间及术中出血、穿孔的发生情况,并对2组患者进行病理组织学疗效评价。[结果]2组患者手术时间及住院时间比较差异无统计学意义。ESD组中有5例发生术中出血,2例发生穿孔;EMR组中有17例发生术中出血,9例发生穿孔。2组患者术中出血、穿孔发生情况比较差异均有统计学意义(χ2=6.853、4.422,P<0.05)。ESD组可能治愈性切除率、非治愈性切除率、肿瘤复发率低于EMR组(χ2=10.225、11.976、10.123,P<0.05),但ESD组一次性完全切除率、治愈性切除率高于EMR组(χ2=22.763、27.991,P<0.05),说明采用ESD治疗早期胃癌更彻底,2组病理组织学疗效评价比较差异均有统计学意义。[结论]采用ESD能有效降低早期胃癌患者术中出血及穿孔的发生情况,病灶切除彻底,肿瘤复发率低,值得在临床上进一步推广。     

内镜黏膜下剥离术诊治高度可疑结直肠癌或癌前病变及共聚焦激光显微内镜在随访中的价值

目的探讨内镜黏膜下剥离术(Endoscopic submucosal dissection,ESD)治疗和诊断高度可疑或早期结直肠癌和癌前病变的有效性和安全性,比较整块活检病理与内镜活检病理对早期癌诊断意义及共聚焦激光显微内镜在随访中的价值。方法对于内镜下高度可疑早期结直肠癌或早期结直肠癌及癌前病变的19例患者行ESD治疗,术后评价ESD治疗相关的一次性整块切除率、组织学治愈性切除率、手术并发症;比较术后整块病理与术前内镜活检诊断符合率;在术后随访时用共聚焦激光显微内镜检查(1、3个月)以指导活检并观察局部复发情况。结果 19处病灶一次性整块切除率为94.7%(18/19),组织学治愈性切除率为84.2%(16/19);病变平均大小(2.3±0.5)cm,平均手术时间(70±19.4)min;术后腹痛2例,延迟性出血1例,内镜下钛夹止血成功,其余病例未发生急性或延迟性出血以及穿孔;术后病理:黏膜内癌7例,癌前病变10例,黏膜下癌2例,其中2例黏膜下癌均进一步补充开腹手术,术后切除病变肠段未发现癌组织残留和周边淋巴结转移;所有病例术后平均随访(24.6±8.0)个月,局部未见残留、复发及异时病灶发生;其中7例黏膜内癌ESD术后1、3个月采用共聚焦激光显微内镜检查以指导活检进行随访未见癌组织残留及复发。19处病灶ESD术后大块组织病理诊断符合率为100%,而术前活检病理诊断符合率仅为57.9%,有统计学意义(P0.01)。结论 ESD具有较高一次性整块切除率和组织学治愈性切除率,是一种治疗和诊断高度可疑或早期结直肠癌病变或癌前病变的安全有效的方法。共聚焦激光显微内镜可能对早期结直肠癌的术后随访具有一定的价值。     

内镜黏膜下剥离术和内镜下黏膜切除术治疗早期食管癌安全有效性的Meta分析

【摘要】目的探讨内镜黏膜下剥离术（ESD）和内镜下黏膜切除术（EMR）在治疗早期食管癌的有效性和安全性方面的差异。方法检索1990年1月至2012年12月Medline、Embase、Cochranelibrary、万方数据库、维普数据库及中国知网数据库上发表的有关早期食管癌ESD和EMR治疗比较研究的所有中英文论文,通过纳入和排除标准筛选后最终纳入文献的效应指标采用Revman5．1软件进行统计分析,以整块切除率、治愈性切除率、局部复发率为有效性效应指标,以穿孔、出血、狭窄和手术时间为安全性效应指标。结果最终纳入8篇非随机对照回顾性队列研究。Meta分析显示,ESD组较EMR组整块切除率[98．36％（360／366）比41．79％（252／603）,P〈0．01]、治愈性切除率[90．81％（168／185）比50．65％（194／383）,P〈0．01]均显著增高,局部复发率[0．55％（2／366）比13．76％（83／603）,P〈0．01]显著降低,穿孔率[4．51％（21／466）比1．25％（8／640）,P=0．03]明显增高,出血率[0．21％（1／466）比0．63％（4／640）,P=0．41]和术后狭窄率[10．48％（39／372）比10．15％（41／404）,P=0．89]差异无统计学意义。结论在早期食管癌的内镜治疗上,ESD的有效性明显优于EMR,安全性则与EMR相似,ESD应作为首选内镜治疗方法。     

内镜黏膜下剥离术和内镜下黏膜切除术治疗早期胃癌的Meta分析

目的评价内镜黏膜下剥离术(ESD)和内镜下黏膜切除术(EMR)治疗早期胃癌(EGC)的疗效和安全性,为EGC内镜下治疗方式的合理选择提供临床依据。方法制定全面检索策略进行检索,结合纳入标准和排除标准获得文献,并进行质量评价,提取相关数据采用Rev Man5.0软件进行Meta分析。结果根据检索策略最初共检出656篇,最终纳入符合入选标准的12篇文献,共纳入5 242个病灶,其中2 692个病灶行ESD治疗,2 550个病灶行EMR治疗。进行Meta分析显示病灶大块切除率(93.11%vs56.71%)、完全切出率(89.05%vs53.21%)及组织治愈性切除率(81.50%vs60.89%)ESD组均高于EMR组;术后复发率ESD组(13/1 737)显著低于EMR组(100/1 888)(OR=0.12,95%CI 0.07~0.22),以上差异均有显著性;但出血发生率ESD组(6.39%)与EMR组(6.32%)基本一致(OR=1.45,95%CI 0.83~2.53);穿孔发生率ESD组(89/2 503)高于EMR组(24/2 500)(OR=3.54,95%CI 2.28~5.50),手术时间ESD组明显长于EMR组(WMD=55.41,95%CI 23.84~86.98),差异均有显著性。结论 ESD治疗EGC的病灶大块切除率、完全切除率、治愈性切除率、复发率等疗效性指标均显著优于EMR组,但安全性指标中ESD组手术时间较长,出血未见改善,且穿孔发生率高,这些均有待技术、设备及操作熟练度的提高和改进。对于老年患者及小病灶,EMR技术仍可酌情选用。     

内镜黏膜下剥离术与传统外科手术治疗消化道早期癌及癌前病变的疗效比较

目的对比内镜黏膜下剥离术(ESD)与传统外科手术治疗消化道早期癌及癌前病变的临床疗效。方法回顾性分析2011年1月至2013年1月本院收治的消化道早癌及癌前病变患者共45例,按照其治疗方式分为ESD组(23例)和手术组(22例),比较两组患者治疗有效性指标、手术相关指标、并发症发生情况和患者预后状况。结果两组治愈性切除率均为100%,但手术组整块完整切除率高于ESD组(P0.05)。ESD组患者手术时间、住院天数和住院费用均低于手术组患者(均P0.05)。两组并发症发生率无统计学差异(P0.05)。随访24个月时,全部患者均存活,未出现原发病灶的转移和复发。结论 ESD治疗消化道早癌和癌前病变的疗效、近期预后与传统外科手术相当,但ESD手术时间、住院时间和住院费用均较传统外科手术低,值得临床推广。     

内镜黏膜下隧道法剥离术治疗胃角巨大黏膜病变的多中心回顾性研究

目的 评估内镜黏膜下隧道法剥离术（ESTD）在治疗胃角巨大黏膜病变中的应用价值。 方法 回顾性分析2014年7月至2016年7月在6家中心接受ESTD或内镜黏膜下剥离术（ESD）治疗的87例胃角大面积黏膜病变患者资料,其中ESTD组32例,ESD组55例。比较2组剥离时间、剥离速度、整块切除率、治愈性切除率、并发症及复发情况。 结果 ESTD组剥离时间较ESD组短［（87.3±32.6）min比（136.7±64.5）min,P＜0.01］,剥离速度明显快于ESD组［（0.18±0.07）cm2／min比（0.08±0.05）cm2／min,P＜0.01］,ESTD组较ESD组整块切除率［100％（32／32）比87.3％（48／55）,P=0.035］及治愈性切除率［100％（32／32）比85.5％（47／55）,P=0.024］高。ESD组术中均有出血发生,有8例出现肌层损伤;而ESTD组术中出血率仅59.4％（19／32）,且无肌层损伤发生（P均＜0.05）。2组复发率比较差异无统计学意义［0（0／32）比1.9％（1／54）,P=0.443］。 结论 ESTD在治疗胃角巨大黏膜病变时具有更高的剥除效率,同时可有效降低手术风险,减少并发症的出现,值得临床推广。     

内镜下黏膜剥离术治疗上消化道早期癌及癌前病变的临床疗效

目的分析内镜下黏膜剥离术(ESD)在上消化道早期癌及癌前病变的治疗价值。方法选取74例上消化道早期癌及癌前病变患者作为研究对象,按手术方式分为ESD组(n=40)与内镜黏膜切除术(EMR)组(n=34),观察两组手术指标差异,比较术后并发症发生情况,随访1年,统计术后复发率,观察患者消化道功能的恢复情况及生活质量的改善状况。结果 (1)ESD组术中出血量少于EMR组,住院时间、创面愈合时间短于EMR组(P0.05);(2)ESD组轻度疼痛所占比例(82.50%)高于EMR组,中重度疼痛所占比例(7.50%、0.00%)均低于EMR组(P0.05);(3)ESD整体并发症发生率为5.00%,低于EMR组的32.35%(P0.05),且其完整切除率高于EMR组(P0.05);(4)术后3、12个月ESD组复发率(2.50%、5.00%)低于EMR组(8.82%、17.65%),但对比差异无统计学意义(P0.05);(5)ESD组术后3、6、12个月生活质量评分均高于EMR组(P0.05)。结论采用ESD治疗上消化道早期癌及癌前病变患者,手术完整切除率高,患者术后恢复快,并发症发生率低,复发少,术后生活质量高。     

Endoscopic mucosal resection and endoscopic submucosal dissection for early gastric cancer: Current and original devices

Compared with endoscopic submucosal dissection (ESD), endoscopic mucosal resection (EMR) is easier to perform and requires less time for treatment. However, EMR has been replaced by ESD, because achieving en bloc resection of specimens > 20 mm in diameter is difficult with EMR. The technique of ESD was introduced to resect large specimens of early gastric cancer in a single piece. ESD can provide precise histological diagnosis and can also reduce the rate of recurrence, but has a high level of technical difficulty, and is consequently associated with a high rate of complications, a need for advanced endoscopic techniques, and a lengthy procedure time. To overcome disadvantages in both EMR and ESD, various advances have been made in submucosal injections, knives, other accessories, and in electrocoagulation systems.     

Technical tips for endoscopic ultrasound-guided hepaticogastrostomy

Interventional procedures using endoscopic ultrasound (EUS) have recently been developed. For biliary drainage, EUS-guided trans-luminal drainage has been reported. In this procedure, the transduodenal approach for extrahepatic bile ducts is called EUS-guided choledochoduodenostomy, and the transgastric approach for intrahepatic bile ducts is called EUS-guided hepaticogastrostomy (EUS-HGS). These procedures have several effects, such as internal drainage and avoiding post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, and they are indicated for an inaccessible ampulla of Vater due to duodenal obstruction or surgical anatomy. EUS-HGS has particularly wide indications and clinical impact as an alternative biliary drainage method. In this procedure, it is necessary to dilate the fistula, and several devices and approaches have been reported. Stent selection is also important. In previous reports, the overall technical success rate was 82% (221/270), the clinical success rate was 97% (218/225), and the overall adverse event rate for EUS-HGS was 23% (62/270). Adverse events of EUS-biliary drainage are still high compared with ERCP or PTCD. EUS-HGS should continue to be performed by experienced endoscopists who can use various strategies when adverse events occur.     

Does endoscopic ultrasound-guided biliary drainage really have clinical impact?

The well established, gold standard method for treatment of obstructive jaundice involves biliary drainage under endoscopic retrograde cholangiopancreatography(ERCP) performed by pancreatobiliary endoscopists. Recently, interventions using endoscopic ultrasound(EUS) have been developed not only for obtaining cytological and histological diagnosis, but also for biliary drainage as alternative method. EUS-guided biliary drainage(EUSBD) was first reported by Giovannini et al. EUS-BD broadly includes EUS-guided rendezvous technique, EUS-guided choledochoduodenostomy, and EUS-guided hepaticogastrostomy. More recently, EUS-guided antegrade stenting and EUS-guided gallbladder drainage have also been reported. many case reports, series, and retrospective studies on EUS-BD have been reported. However, because prospective studies and comparisons between the different biliary drainage methods have not been reported, the technical success, functional success, adverse events, and stent patency with long-term follow up of EUS-BD are still unclear. Therefore, prospective, randomized controlled studies addressing these issues are needed. Despite this, EUSBD undoubtedly is clinically useful as an alternative biliary drainage method. EUS-BD has the potential to be a first-line biliary drainage method instead of ERCP if results of clinical trials are favorable and the technique is simplified.     

超声内镜对食管静脉曲张结扎术前后侧枝循环变化的临床研究

目的 应用Fujinon SP-701小探头超声内镜观察食管静脉曲张结扎术(EVL)前后曲张静脉及侧枝循环的变化，分析影响疗效的原因。选择合理的治疗方法。方法 对60例单纯食管静脉曲张出血患者依超声检查结果分为3组：Ⅰ组为单纯食管静脉曲张(EV)；Ⅱ组为合并有食管旁静脉(PEV)，但无交通枝(PV)；Ⅲ组合并有食管旁静脉及交通枝。患者EVL术后4、8、12周行超声内镜检查，观察及测量EV、PEV、PV的变化情况，分析影响疗效的原因。结果 Ⅰ组显效率75％，复发率16％，疗效最佳；Ⅲ组显效率0％，复发率100％，疗效最差。Ⅰ组24例中出现PEV者12例；Ⅱ组20例PEV全部增宽，11例出现PV；Ⅲ组全部有PEV增宽、PV增多增宽表现。结论 超声内镜对食管静脉曲张出血治疗方法的选择有指导意义。单纯食管静脉曲张EVL可获得满意疗效，但是伴PEV及PV者不是EVL适应证，建议采用其他方法治疗。     

ERCP结合EPT对胆囊切除术后患者诊治价值的探讨

目的 回顾性研究逆行性胰胆管造影（ERCP）结合乳头肌切开术（EPT）对胆囊切除术后患者的诊治价值。方法 170例胆囊切除术后症状再发或反复发作患者，接受ERCP检查和EPT等治疗，诊断结果与B超作对照。同时动态观察内镜下介入诊治术后临床表现的改变。不良反应及血清淀粉酶的变化及高淀粉酶血症的分布情况。结果 经ERCP结合EPT等术后患者临床症状显著改善；与B超对照ERCP对胆囊切除术后胆总管残余结石的诊断率显著提高（P＜0．001），对胆总管扩张程度的诊断价值显著优于B超（P＜0．05），并能发现许多B超检查不能发现的胆胰病变；术后主要不良反应表现为出血、高淀粉酶血症，ERCP结合EPT等治疗组高淀粉酶的发生率显著高于单纯ERCP操作组（P＜0．01）。经积极地处理后短期内出血控制，血清淀粉酶多在3日内转为正常。结论 对胆囊切除术后患者，ECRP结合EPT不失为一项非常有价值、安全的诊治措施。     

Endoscopic treatment of gastro-oesophageal reflux disease (GORD): a systematic review

Gastro-oesophageal reflux disease represents an extremely common disorder which has a substantial impact on patients' quality of life and use of health care resources. Gastro-oesophageal reflux disease is a chronic relapsing disease for which a lifelong solution is needed. Until now the two competing therapeutic modalities have been the medical and surgical therapies. Quite recently a third option has become available. A number of endoscopic anti-reflux procedures have been described, with the common goal of creating an anti-reflux barrier, thus obviating long-term proton pump inhibitors and the cost and potential risk of laparoscopic Nissen fundoplication. In this review the different techniques are thoroughly examined and the results are critically evaluated, giving special emphasis to efficacy, safety and durability of these new anti-reflux procedures. Available data show that these anti-reflux techniques produce significant improvement in gastro-oesophageal reflux disease symptomatology and quality of life as well as reduce the use of anti-reflux medication, without causing serious morbidity or mortality. However, the majority of these techniques have failed to adequately control oesophageal acid reflux. Endoscopic anti-reflux therapies therefore sound very attractive-being less invasive than surgery-and show a significant promise, but are still in the early stages of assessment. Large-scale randomized multi-centre trials comparing control groups with sham procedures are essential to confirm their efficacy. Further studies are also necessary to determine what modifications these techniques require in order to produce maximum clinical efficacy and durability. However, considering that current therapies (both medical and surgical) of gastro-oesophageal reflux disease are highly effective, the need for such new endoscopic modalities may be questionable. Moreover, appropriate trials in dedicated centres should be carried out to assure that the enthusiasm commonly associated with new technology is justified and can be generalized to open-access endoscopists.     

Endoscopic Ultrasound-Guided Hepaticogastrostomy: Technical Review and Tips to Prevent Adverse Events

Most patients who require biliary drainage can be treated by endoscopic retrograde cholangiopancreatography (ERCP)-guided procedures. However, ERCP can be challenging in patients with complications, such as malignant duodenal obstruction, or a surgically-altered anatomy, such as a Roux-en-Y anastomosis, which prevent advancement of the duodenoscope into the ampulla of Vater. Recently, endoscopic ultrasound (EUS)-guided biliary drainage via transhepatic or transduodenal approaches has emerged as an alternative means of biliary drainage. Typically, EUS-guided gallbladder drainage or choledochoduodenostomy can be performed via both approaches, as can EUS-guided hepaticogastrostomy (HGS). EUS-HGS, because of its transgastric approach, can be performed in patients with malignant duodenal obstruction. Technical tips for EUS-HGS have reached maturity due to device and technical developments. Although the technical success rates of EUS-HGS are high, the rate of adverse events is not low, with stent migration still being reported despite many preventive efforts. In this review, we described technical tips for EUS-HGS related to bile duct puncture, guidewire insertion, fistula dilation, and stent deployment, along with a literature review. Additionally, we provided technical tips to improve the technical success of EUS-HGS.     

Small sphincterotomy combined with endoscopic papillary large balloon dilation vs sphincterotomy alone for removal of common bile duct stones

AIM: To evaluate the efficacy and safety of endoscopic papillary large diameter balloon dilation (EPLBD) following limited endoscopic sphincterotomy (EST) and EST alone for removal of large common bile duct (CBD) stones.METHODS: We retrospectively compared EST + EPLBD (group A, n = 64) with EST alone (group B, n = 89) for the treatment of large or multiple bile duct stones. The success rate of stone clearance, procedure-related complications and incidents, frequency of mechanical lithotripsy use, and recurrent stones were recorded.RESULTS: There was no statistically significant difference between the two groups regarding periampullary diverticula (35.9% vs 34.8%, P > 0.05), pre-cut sphincterotomy (6.3% vs 6.7%, P > 0.05), size (12.1 ± 2.0 mm vs 12.9 ± 2.6 mm, P > 0.05) and number (2.2 ± 1.9 vs 2.4 ± 2.1, P > 0.05) of stones or the diameters of CBD (15.1 ± 3.3 mm vs 15.4 ± 3.6 mm, P > 0.05). The rates of overall stone removal and stone removal in the first session were not significantly different between the two groups [62/64 (96.9%) vs 84/89 (94.4%), P > 0.05; and 58/64 (90.6%) vs 79/89 (88.8%), P > 0.05, respectively]. The rates of post-endoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasemia were not significantly different between the two groups [3/64 (4.7%) vs 4/89 (4.5%), P > 0.05; 7/64 (10.9%) vs 9/89 (10.1%), P > 0.05, respectively]. There were no cases of perforation, acute cholangitis, or cholecystitis in the two groups. The rate of bleeding and the recurrence of CBD stones were significantly lower in group A than in group B [1/64 (1.6%) vs 5/89 (5.6%), P < 0.05; 1/64 (1.6%) vs 6/89 (6.7%), P < 0.05, respectively].CONCLUSION: EST + EPLBD is an effective and safe endoscopic approach for removing large or multiple CBD stones.     

Endoscopic polypectomy： A promising therapeutic choice for esophageal carcinosarcoma

Esophageal carcinosarcoma is a rare malignant tumor composing of both carcinomatous and sarcomatous elements. Endoscopic therapy is less invasive and may represent an alternative to esophagectomy for superficial esophageal carcinosarcoma. Here, we report a 61-year-old male who was diagnosed as esophageal carcinosarcoma and underwent endoscopic polypectomy with well tolerance and favorable prognosis. We also present a brief review of the literature.